Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

Abstract: Disclosed herein are Complement factor H (CFH) antibodies and methods of using the antibodies.

Abstract: Disclosed herein are Complement factor H (CFH) antibodies and methods of using the antibodies.

Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.

Abstract: Methods, kits, and compositions for detecting and/or treating cancer based on detecting and/or administering an antibody, which can optionally be a bispecific antibody, having the immunoreaction characteristics of a cancer-associated autoantibody; an antigen for a cancer-associated autoantibody; or both an antibody having the immunoreaction characteristics of a cancer-associated autoantibody and an antigen for a cancer-associated autoantibody, in or to a subject in need thereof.

Abstract: The presently disclosed subject matter provides ligands for detecting and imaging cancer cells and tumors, and for guided delivery of an active agent to cancer cells and tumors. In some embodiments the ligands comprise an antibody fragment, wherein the antibody fragment comprises a VHH domain. In some embodiments a composition is provided for targeting of cancer cells or tumors. Also provided are methods for delivery of a composition to a target tissue or tumor in a subject. Also provided are methods for imaging a target tissue or tumor in a subject. In some embodiments methods for treating a tumor in a subject are provided. Also provided are methods for diagnosing a tumor in a subject.

Abstract: Methods and kits are provided for determining the probability of lung cancer, for managing treatment of subjects with potential lung cancer and for molecular staging of lung tumors. The methods include determining an amount of each member of a panel of biomarkers in a sample from the subject, wherein the panel of biomarkers comprises at least two of the proteins alpha-1-antitrypsin, carcinoembryonic antigen, squamous cell carcinoma antigen, retinol binding protein, transferrin, and haptoglobin; and assigning the subject to a group having a higher or lower probability of lung cancer based on the determined amount of each biomarker the panel.

Abstract: The present invention relates generally to systems and methods for determining differential protein expression, and diagnostic discovery systems and methods that utilize the same. In particular, the present invention relates to a system and method of obtaining and analyzing protein profiles to determine protein patterns associated with clinical parameters and manifestations of disease and to discover specific biomarkers that are characteristic of diseases such as cancer. The present invention further relates to the identification of potential molecular targets for diagnostic applications and/or therapeutic intervention.

Abstract: A cell protein profiling and diagnostic system is provided that fractionates a protein content of a tissue sample into protein subgroups, independently performs mass spectroscopy on each protein subgroup, creates a cell expression protein profile from the mass spectra, and identifies protein patterns associated with subject characteristics, such as biological conditions and diseases, based on the cell expression protein profile. In one embodiment, the protein patterns are identified with an artificial neural network, or other data mining or pattern recognition techniques.